Gilead and Glympse Bio Announce Strategic Collaboration for Use of Biomarker Technology in NASH Clinical Development
Gilead Sciences Inc. (Nasdaq: GILD) and Glympse Bio, Inc., today announced that the companies have entered into a strategic collaboration in nonalcoholic steatohepatitis (NASH) clinical development. Glympse Bio’s proprietary synthetic biomarkers – bioengineered to identify stage and progression of disease as well as early detection of treatment response – will be used to determine clinical trial participants’ stage of disease at initial screening and to determine responses to study treatment in Gilead’s NASH clinical program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191028005145/en/
“We are excited about the opportunity to partner with Glympse Bio to help inform our NASH development program,” said Mani Subramanian, MD, PhD Senior Vice President, Liver Diseases, Gilead Sciences. “By utilizing this innovative technology, we hope to better characterize this complex disease and improve our understanding of how our compounds impact disease progression.”
Glympse Bio’s proprietary technology, Glympse Inside™, combines synthetic biomarkers with machine learning approaches to identify the stage and monitor progression of important, complex diseases such as cancer, fibrosis, inflammation, and infections, in real time.
“We are very excited about partnering with Gilead, a leader in drug development, to help drive earlier and more favorable outcomes for patients,” said Caroline J Loew, President and CEO, Glympse Bio. “Gilead’s commitment to developing innovative medicines in areas of high unmet medical need aligns with our mission of transforming disease detection and measuring treatment response, all with the goal of helping improve the lives of patients.”
Financial terms of the agreement were not disclosed.
About Glympse Bio
Glympse Bio is pioneering the development of disruptive, non-invasive technology to directly query disease activity inside the body. The Company’s proprietary synthetic biomarkers – biological sensors developed using breakthroughs in science, engineering, medicine and artificial intelligence – are potentially tunable to a multitude of diseases and offer earlier measures of response to disease and treatment. By integrating real-time biological activity with sophisticated machine learning and artificial intelligence, Glympse Inside™ is a pan-disease product engine that aims to transform disease monitoring and treatment response. The company is based at the Lab Central incubator in Cambridge, MA. For more information, please visit http://www.glympsebio.com.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
Gilead Forward-Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that the parties may not realize the potential benefits of this collaboration. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191028005145/en/
Contact information
Sung Lee, Investors
(650) 524-7792
Beth Kurth
(617) 584-9650
bkurth@conwaycommsir.com
Arran Attridge, Media
(650) 425-8975
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Experian Announces New Commitment to a Flexible Working Culture11.5.2021 19:26:00 EEST | Press release
Experian, the global information services company, has today announced a new global approach to work. The aim is to take the learnings from the experience of Covid-19 lockdown and create a working environment which suits everyone’s situation. Experian is committing to promote more individual choice by creating a new hybrid model, where employees will be encouraged to ‘work your way’. Through the lockdown, Experian moved its global operations to remote working with very limited disruption. Most employees will be offered increased flexibility, with the majority moving to a hybrid model, some working fully remotely, and some in the office. Experian – which operates in 45 countries around the world – believes this will continue to boost productivity and improve the work / life balance options for its 17,800 global employee base. What the Covid-19 crisis has reminded us, beyond everything else, is that we are all individuals living very different lives. That’s prompted Experian to go down t
SentinelOne is the Only Vendor to Score Highest Across All Three Gartner Critical Capabilities Use Cases11.5.2021 18:40:00 EEST | Press release
SentinelOne, the autonomous cybersecurity platform company, today announced that Gartner has positioned SentinelOne with the highest scores in all three use cases; Type A, B, & C in Gartner’s 2021 Critical Capabilities for Endpoint Protection Platforms report1. Out of the 19 vendors included in the report, SentinelOne is the only vendor that received the highest score across all three Critical Capabilities use cases: Customer use case Type A is focused on “lean forward” organizations that adopt new technologies very early in the adoption cycle. Customer use case Type B is focused on “overall value” by weighing the risks of the early use of new technology against the benefits. Customer use case Type C represents organizations that typically view technology as an expense or operational necessity and use it as a means to reduce costs. “We believe receiving the highest product score across all three customer use cases in the 2021 Critical Capabilities for Endpoint Protection Platforms vali
1E Challenges DEM Market to Deliver More, Launching New Unified eXperience Management Category11.5.2021 17:35:00 EEST | Press release
1E , innovators in endpoint management, today announced Unified eXperience Management (UXM) , a new category that seeks to address the siloed approach inherent in tools in the Digital Experience Monitoring (DEM) space. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005842/en/ 1E Tachyon Platform: Unified eXperience Management to improve the Digital Experience of all employees (Graphic: Business Wire) Due to the relative immaturity of the Digital Experience Management category, most tooling is focused on identifying and reporting on the scale of the problem, scoring, and issue identification. These tools create analytics silos that give insight, but are uncoupled from the automation technology that can actually improve end-user experience at an enterprise scale. Meanwhile, employees are becoming increasingly more frustrated, with 56% feeling dissatisfied with their IT experience. Organizations looking to improve the dig
Biorasi Receives ISO 9001:2015 Certification for Quality Management11.5.2021 17:30:00 EEST | Press release
Biorasi, a leading global full-service contract research organization (CRO), is proud to announce the achievement of ISO 9001:2015 certification. By earning this ISO accreditation, Biorasi has demonstrated dedication to the practice of quality assurance within the clinical trials industry and commitment to quality excellence for individual clinical studies. “ISO 9001:2015 certification is a big deal for Biorasi,” said Chris O’Brien, CEO at Biorasi. “It is a powerful, independent validation of the quality of our processes. It sends a message to potential sponsors across the globe that Biorasi cares deeply about quality. It tells them they can trust us.” Biorasi was presented with their ISO 9001:2015 certification on May 5, 2021, joining the ranks of other quality-focused organizations, including our preferred vendor, IBM Watson Health. “Our Quality Policy is driven by the fundamental understanding that patients and their families are affected by the decisions we make,” said Todd Brill,
Alvotech Seeks to End AbbVie’s Wrongful Monopoly on Humira and Bring Affordable Arthritis Treatment to U.S.11.5.2021 17:23:00 EEST | Press release
Alvotech today filed a federal lawsuit (Case 1:21-cv-00589) seeking to end the monopoly that pharmaceutical giant AbbVie has long-maintained on the adalimumab market, sold as Humira. Humira is the highest grossing prescription drug in the United States with over $16 billion in sales in 2020 (nearly $20Bn globally). Alvotech has developed a biosimilar (analogous to a generic) of Humira called AVT02, the first-filed biosimilar drug equal in strength to Humira’s latest formulation, which AbbVie markets as a high-concentration, pain-free drug. The company is also developing AVT02 as an interchangeable product and it expects results from its ongoing interchangeability study in Q2 of this year. AVT02 could save U.S. taxpayers and the overall healthcare system $8-10 billion annually. “Our new product will be a gamechanger that will provide consumers who are suffering from chronic pain with significant savings, and we look forward to bringing this drug onto the market as soon as possible,” sai
The United Kingdom: Biolog-id and Nicholson Consulting Ltd Cooperate to Develop a Demonstration Lab to Showcase Biolog Transfusion Solution11.5.2021 16:01:00 EEST | Press release
Biolog-id, a global service provider of connected healthcare solutions, and Nicholson Consulting Ltd, an innovative consulting and engineering company specialized in the blood transfusion field, join their forces to set up a demonstration lab located at Malvern Hills Science Park, in the south of Birmingham. This co-branded demo environment will showcase to the UK market the biolog-id’s cutting-edge product-line: Biolog Transfusion Solution. Based on the RFID technology, Biolog Transfusion Solution has been designed to respond to the needs of all the actors involved along the blood transfusion supply chain. By combining software, equipment and tags, this breakthrough innovation offers to manage in real-time each application area, from collection and manufacturing at the blood centre, central and remote inventory at the blood banks to blood compound administration at patient’s bedside. Flexible and reliable, the biolog-id technology generates value throughout the lifecycle of blood prod
Kong Konnect Now Generally Available With Multi-Geo Support: Offers End Users Breakthrough API and Microservices Connectivity11.5.2021 16:00:00 EEST | Press release
Kong Inc., the cloud connectivity company, today announced the general availability release of Kong Konnect, a service connectivity platform that enables the modern connected business. First previewed at Kong Summit 2020 in private beta, Kong Konnect provides end users with instant access to a comprehensive suite of tools that enable reliable, secure and observable connectivity across their APIs and microservices. The GA release features new multi-geo support, allowing users to physically locate services close to their businesses for privacy and regulatory compliance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005311/en/ The fully modular platform enables developers, architects and operators to accelerate application development cycles and provide connectivity between services for stellar digital experiences. Architects decouple connectivity concerns from microservices so that developers can focus on building appli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom